{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Designated
Source:
FDA ORPHAN DRUG:768020
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
FDA ORPHAN DRUG:880622
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
FDA ORPHAN DRUG:675618
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:926722
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
FDA ORPHAN DRUG:736720
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
ML355 is a potent and selective inhibitors of 12-Lipoxygenase(12-LOX) with IC50 of 0.34 uM. It has excellent selectivity over related lipoxygenases and cyclooxygenases. ML355 has favorable absorption, distribution, metabolism, and excretion (ADME) properties, inhibits PAR-4 induced aggregation and calcium mobilization in human platelets, and reduces 12-HETE in mouse/human beta cells suggesting its potential utility in animal models for antiplatelet therapy and diabetes.
Status:
Designated
Source:
FDA ORPHAN DRUG:830021
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Designated
Source:
FDA ORPHAN DRUG:269408
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Designated
Source:
FDA ORPHAN DRUG:731720
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:696219
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Designated
Source:
FDA ORPHAN DRUG:761020
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
